Kpf Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 15-12-2024
- Paid Up Capital ₹ 0.10 M
as on 15-12-2024
- Company Age 45 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 12.37 Cr
as on 15-12-2024
- Revenue -41.70%
(FY 2022)
- Profit 136.99%
(FY 2022)
- Ebitda 44.57%
(FY 2022)
- Net Worth 12.18%
(FY 2022)
- Total Assets -2.25%
(FY 2022)
About Kpf Lifesciences
The Corporate was formerly known as Grapharts Repro-Packs Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹12.37 Cr.
Rakesh Sajjan and Vedant Gupta serve as directors at the Company.
- CIN/LLPIN
U22220MH1979PTC021249
- Company No.
021249
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 1979
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Kpf Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Sajjan  | Director | 01-Jan-2004 | Current |
| Vedant Gupta | Director | 16-Oct-2010 | Current |
Financial Performance of Kpf Lifesciences.
Kpf Lifesciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 41.7% decrease. The company also saw a substantial improvement in profitability, with a 136.99% increase in profit. The company's net worth Soared by an impressive increase of 12.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kpf Lifesciences?
In 2022, Kpf Lifesciences had a promoter holding of 55.00% and a public holding of 45.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Konark Herbals And Healthcare Private LimitedActive 3 years 6 monthsRakesh Sajjan and Vedant Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Feb 2019 | ₹4.38 Cr | Open |
Others Creation Date: 28 Dec 2017 | ₹2.88 Cr | Open |
Others Creation Date: 30 Nov 2017 | ₹1.11 Cr | Open |
How Many Employees Work at Kpf Lifesciences?
Unlock and access historical data on people associated with Kpf Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kpf Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kpf Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
